Oncolytic vaccinia virus combination cancer therapy
AssigneeJennerex, Inc.
InventorsDavid Kirn, Caroline Breitbach
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
Claims29
A method for treating cancer in a subject previously administered a poxvirus therapy comprising administering an effective amount of an anti-angiogenic agent.
A method for treating a hepatic tumor in a patient comprising administering sorafenib to the tumor, wherein the tumor i) was previous treated with a vaccinia virus expressing GM-CSF and ii) was determined to be undergoing reperfusion.
A method of treating a hepatic tumor comprising:
- (a) administering an effective amount of a vaccinia virus expressing GM-CSF;
- and,
- (b) administering sorafenib to a tumor determined to be undergoing reperfusion.
A method of treating a hepatic tumor comprising administering an effective amount of a vaccinia virus expressing GM-CSF, wherein the tumor will be evaluated for reperfusion and determined to be a candidate for sorafenib therapy if the tumor is undergoing reperfusion.
A method of treating a patient having a tumor comprising:
- (a) evaluating a tumor that has been treated with an anti-cancer therapy by non-invasive imaging of the tumor to detect reperfusion;
- and
- (b) administering an effective amount of sorafenib to a tumor in which reperfusion is detected.
A method of sensitizing a patient to an anti-angiogenic therapy comprising administering an effective amount of a pox virus.
Dependencies are inferred from the claim text.